N-type calcium channel and renal injury

Lei Bai1 · Shichao Sun2 · Yao Sun3 · Fujun Wang1 · Akira Nishiyama4

Received: 16 November 2021 / Accepted: 15 March 2022 / Published online: 13 April 2022 © The Author(s) 2022

Abstract
Accumulating evidences indicated that voltage-gated calcium channels (VDCC), including L-, T-, N-, and P/Q-type, are present in kidney and contribute to renal injury during various chronic diseases trough different mechanisms. As a voltage-gated calcium channel, N-type calcium channel was firstly been founded predominately distributed on nerve endings which control neurotransmitter releases. Since sympathetic nerve is distributed along renal afferent and efferent arterioles, N-type calcium channel blockade on sympathetic nerve terminals would bring renal dynamic improvement by dilating both arterioles and reducing glomerular pressure. In addition, large body of scientific research indicated that neurotransmitters, such as norepinephrine, releases by activating N-type calcium channel can trigger inflammatory and fibrotic signaling pathways in kidney. Interestingly, we recently demonstrated that N-type calcium channel is also expressed on podocytes and may directly contribute to podocyte injury in denervated animal models. In this paper, we will summarize our current knowledge regarding renal N-type calcium channels, and discuss how they might contribute to the river that terminates in renal injury.

Keywords N-type calcium channel · Sympathetic nerve · Podocyte · Renal injury

Introduction
Voltage-gated calcium channels can be classified into L-, P/Q-, N-, R-, and T-type subtypes according their pharmacological and electrophysiological characters. In the kidney, a number of calcium channels comprising various α1 subunits, including $\text{Ca}^{2+}_{V2.1}$ (α1A), $\text{Ca}^{2+}_{V1.2}$ (α1C), $\text{Ca}^{2+}_{V1.3}$ (α1D), $\text{Ca}^{2+}_{V3.1}$ (α1G), and $\text{Ca}^{2+}_{V3.2}$ (α1H), are expressed, and function as L-type ($\text{Ca}^{2+}_{V1.2}$, $\text{Ca}^{2+}_{V1.3}$), T-type ($\text{Ca}^{2+}_{V3.1}$, $\text{Ca}^{2+}_{V3.2}$), and P/Q-type ($\text{Ca}^{2+}_{V2.1}$) calcium channels. Furthermore, the kidney is supplied with numerous nerve endings that contain N-type (α1B) $\text{Ca}^{2+}$ channels [1]. Recently we indentified N-type calcium channel expression in podocyte from both in vivo and in vitro experiments [2].

N-type calcium channel in renal dynamic changes
Numerous studies have already reported that N-type voltage dependent calcium channels predominantly distributed in neuronal, especially sympathetic neuronal cells. These channels were intimately involved in sympathetic neurotransmission and regulated the release of norepinephrine from sympathetic nerve endings [3–7]. This founding was clarified and supported by applying various N-type calcium channel antagonists in both in vivo [8–11] and clinical researches [12–14]. Underlying mechanisms could be simply summarized as follow: Calcium influx which mainly through voltage gated calcium channels in nerve endings will interact with soluble NSF attachment protein receptor (SNARE) proteins on synaptic vesicle and nerve terminal membranes. This interaction in turn causes exocytosis of neurotransmitters (e.g. NE) from the vesicles [15]. Although some neurons elicited resistant to N-type calcium channel antagonists suggested co-existence of other type calcium channels [16], N-type calcium channel still been believed
as the main channel in mediating calcium influx in sympathetic nerves [3]. Abnormal activations of sympathetic nerve which innervated renal afferent and efferent arterioles have been indicated to play an important role in renal injury [17, 18]. Morphological studies clearly showed marked narrowing of afferent and efferent glomerular arterioles in the kidney during renal sympathetic nerve stimulation [19]. The insufficient oxygen and nutrient supply which due to significant reduced renal blood flow may underlie this renal dynamic injury. In contrast, renal denervation was verified by demonstrating a 50% decrease in renal norepinephrine spillover which resulted in a long-term reduction in arterial pressure [20]. Moreover, L-type calcium channel blockade causes predominant dilation of afferent arteriole. During hypertension, it will transmit systemic high blood pressure to kidney which potentially results in glomerular injury [21], whereas, N-type calcium channel inhibition decreases glomerular pressure by dilating both afferent and efferent arterioles [22].

Since excitation–contraction coupling in most resistance vessels is largely dependent on calcium influx through voltage-dependent calcium channels in rat kidney [23, 24], and local expressions of L- and T-type calcium channels already have been identified in smooth muscle cells which isolated from preglomerular vessels [25]. It is widely accepted that L- and T-type calcium channels are responsible for renal dynamic changes by controlling dilation or contraction of afferent and efferent arterioles. However, one issue raised since long time ago: L- and T-type VDCCs cannot fully account for calcium influx in renal vascular smooth muscle cells [26]. Hansen et al. indicated the possible involvement of neuro-type calcium channel (e.g., P-/Q-type) in depolarization-mediated contraction in renal afferent arterioles [27]. Recently, both gene and protein expression of N-type calcium channel has been identified in dog basilar artery smooth muscle cells by Nikitina et al. [28], suggesting that, in addition to neural control, N-type calcium channel may also directly contribute to contraction of renal vessels by mediating calcium influx in vascular smooth muscle cells (Fig. 1).

### N-type calcium channel in renal non-dynamic changes

Besides renal vascular effects, N-type calcium channel has also been proved involve in non-dynamic changes during renal damage. An activated sympathetic nervous system was often characterized in chronic kidney disease, end-stage renal disease as well as diabetic nephropathy [29–33]. Therefore, neurotransmitter, such as norepinephrine, has been indicated as a mediator of sympathoexcitation induced renal injury by triggering some fibrotic and inflammatory signaling pathways in kidney. Reno-protective effects of N-type calcium channel inhibition were considered, at least partially, depend on inhibiting norepinephrine releases and thereby interfere with the fibrotic and inflammatory signaling pathways [9].

**N-type calcium channel and renal rennin-angiotensin system (RAS)**

Cilnidipine showed superior effect in preventing proteinuria in hypertensive patients when compared with amlodipine [34–36]. These evidences from clinical trials suggested the unique contribution of N-type calcium channel blockade to renal injury should be independent of blood pressure control. Thus people try to figure out how does N-type calcium channel inhibition contribute to renal protection and elucidate possible involved mechanisms. Renin-angiotensin system is one of the hottest pathways may underlie this process.

Recent years, local RAS has been demonstrated as major role in pathogenesis of renal injury rather than circulating RAS. In the kidney, all of the RAS components are present and modulated by independent multiple mechanisms. For example, angiotensin II, the most powerful biologically active product of the RAS has been found be differently regulated in organs. In particular, the Ang II contents in renal tissues are much higher than can be explained on the basis of equilibration with the circulating concentrations [37–39]. This locally produced Ang II induces inflammation, cell growth, mitogenesis, apoptosis, migration, and differentiation, regulates the gene expression of bioactive substances, and activates multiple intracellular signaling pathways, all of which might contribute to tissue injury [40].

Since direct measurements of the intrarenal RAS components or micropuncture investigations in human subjects are not available, we may find our answers by applying in vivo studies. Cilnidipine treatment elicited significant stronger inhibition on albuminuria glomerular hypertrophy and interstitial fibrosis in dahl rats. In contrast, L-type calcium channel blocker, amlodipine did not show any effect on these parameters. In addition, urinary norepinephrine excretion, renal expression of renin mRNA and renal tissue levels of angiotensin II were increased only in the amlodipine-treated group [41]. Cilnidipine has been demonstrated more effective than, L-type calcium channel blocker amlodipine for preventing kidney injury in dahl rats [21, 41, 42]. This effect cannot be only explained by the L-type calcium channel blocking action that lowered blood pressure, but can be partially explained by the N-type calcium channel blocking action that lead to suppression of the sympathetic nerve activity and renal rennin-angiotensin system.

Consistent founding has been reported by Toba, H. Glomerulosclerosis and collagen deposition in the tubulointerstitial area was significant attenuated by cilnidipine.
administration in DOCA-salt hypertensive rats. Importantly, accompany with these reno-protections, the renal activity and expression of angiotensin-converting enzyme (ACE) and the aldosterone concentration were inhibited by cilnidipine as well. However, these renal changes have not been observed in amlodipine treated group [43].

Activation of the renal renin-angiotensin system in diabetic patients always appears to contribute to diabetic nephropathy. Previously we investigated effects of cilnidipine on type 2 diabetic nephropathy by using SHR/ND rats. Vehicle treated group showed markedly increased urinary protein compared with healthy controls. Significant increased Ang II content and angiotensinogen mRNA expression were also detected in kidney. After 20 weeks treatment, cilnidipine significantly inhibited proteinuria, renal Ang II content and angiotensinogen mRNA expression. However, amlodipine did not elicit any effects on these parameters, despite anti-hypertensive effect [2]. Again, this founding suggested N-type calcium channel blockade may contribute to reno-protection by inhibiting the activated renal RAS in diabetic nephropathy. Moreover, renal AT1R has been reported to be significantly elevated in chronic pathogenesis which was believed associated with excessive renal sympathetic nerve activity. Renal denervation decreased this renal AT1R overexpression [44]. The possible relation of renal sympathetic nerve and RAS was suggested in in vitro study as well; Wang et.al. demonstrated that exogenous norepinephrine stimulates the expression of the AGT gene in the renal proximal tubule and which thereby increases the formation of local renal Ang II [45].

Taken together, renal RAS was inappropriately activated and play a critical role in renal injury during chronic renal diseases, hypertension and diabetic nephropathy. N-type calcium channel blockade may inhibit local RAS through,
at least partially through, its neural control in kidney. The possible underlying mechanism can be summarized as follows: During pathological conditions, N-type calcium channel on renal sympathetic nerves was activated for mediating calcium influx which in turn triggered neurotransmitter release (e.g., norepinephrine). This elevated renal norepinephrine can induce upregulation of components of RAS in kidney lead to increase of angiotensin II, the major effective molecule of RAS which ultimately contribute to renal injury. N-type calcium channel inhibition can attenuate the inappropriate activation of RAS by preventing norepinephrine releases from sympathetic nerve in kidney.

However, local RAS activation cannot be fully explained by neural control. Our recent study suggested that N-type calcium channel blockade induced inhibition on renal RAS may independent of renal sympathetic nerve. In that study both renal norepinephrine and Ang II are significantly elevated in innervated vehicle treated-SHR rats. However, we also clearly demonstrated that cilnidipine significantly inhibited renal Ang II in renal denervated spontaneous hypertensive rats (SHR). In contrast, amlodipine did not show any effect on renal Ang II. Moreover, renal denervation just slightly decreased renal Ang II level in vehicle treated SHR, suggested two things: (1) Cilnidipine induced inhibition on renal RAS should be attributed to its N-type calcium channel blocking action. (2) However, this inhibition could be independent of renal sympathetic nervous system. There should be some other pathways have also been involved in N-type calcium channel mediated activation of renal RAS. Recent in vitro studies have already demonstrated existence of local RAS which can be activated by high glucose or mechanical stretch in various renal cells including mesangial cells [46, 47], proximal tubular cells [48–51], especially in podocytes [52–54]. During past decades, as a critical role in development of proteinuria and glomerulosclerosis, podocytes injury became a hot topic in research field of renal damage. We previously demonstrated that upregulation of N-type calcium channels in podocytes is company with significant elevated renal Ang II in diabetic nephropathy and hypertensive animal models. As indicated by Nitschke R, Ang II significantly increased intracellular calcium activity in podocytes via AT1 receptor. However, L-type calcium channel blocker, nicardipine, failed to inhibit this intracellular calcium activity, suggested that this AT1R mediated activation of intracellular calcium activity may be dependent on other calcium channels. In addition of identified N-type calcium channel on podocyte, we found exogenous Ang II induces significant increase of N-type calcium channel mRNA expression in cultured podocytes.

Nuclear factor κB (NFκB) has been suggested be activated and play a critical role in renal damage during hypertension and diabetes in both in vivo and in vitro studies [55–59]. Augmented intracellular calcium concentration has been indicated for mediating activation of NFκB signaling pathway in proximal tubular cells [60]. Moreover, as a transcriptional factor, NFκB has also been shown to modulate the rat and human AGT gene expression [61–63]. Since almost all components exist in podocyte [52], elevated AGT synthesis may finally lead to increase of Ang II production. Therefore, combined with our previous research, there may be a positive feedback between Ang II and N-type calcium channels. Activation of N-type calcium channel could be both consequence and cause of evoked renal RAS. Some factors, such as NFκB, maybe involved as parts or mediators of this vicious loop (Fig. 2).

**N-type calcium channel and renal oxidative stress**

Among various factors involved in renal injury, oxidative stress, the imbalance of pro- and anti-free radical processes and the formation of excessive free radicals, also attracted enormous attention [64, 65].

Remarkable increase of renal reactive oxygen species (ROS) production has been reported in different hypertensive [66–69] and diabetic [70–73] animal models via a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-dependent manner [74]. Accumulating evidence from both in vivo and in vitro studies further elucidated specific contribution of ROS overproduction to renal injury by targeting different cell types: Oxidant-mediated injury to tubular cells was suggested to play a critical role in tubulointerstitial fibrosis [75–78]. High glucose induces proliferation and extracellular matrix (ECM) synthesis of mesangial cells through activating NADPH oxidase which thereby cause ROS production [79–81]. In addition, mitochondrial dysfunction of mesangial cells also been reported could be induced by oxidative stress during high glucose condition [82]. Protein kinase C, mitogen-activated protein (MAP) kinase and NFκB have been implicated in the ROS overproduction induced abnormalities of mesangial cells [81, 83, 84]. In glomerular hypertension, where mechanical strain induced activation of extracellular signal-regulated protein kinases (ERK) was implicated in ECM deposition [85, 86]. Yatabe et.al. demonstrated mechanical strain induces phosphorylation of extracellular signal-regulated protein kinases (ERK) which mediated by activating NADPH oxidase in mesangial cells [87]. Continuous results also demonstrated that mechanical strain induced matrix production in mesangial cells through activating RhoA requires NADPH oxidase-mediated ROS generation [88]. Podocyte injury has also been associated with overactivation of ROS. High glucose induced podocyte hypertrophy has been implicated through a ROS-dependent activation of ERK1/2 and Akt/PKB [89]. Oxidative stress mediated podocyte apoptosis via activating p38 mitogen-activated protein kinase and caspase...
3 has been suggested in cultured podocytes and db/db mice by Susztak et al.[90]. Thus, numerous studies focused on renal antioxidant therapies for preventing renal damage during past decades.

Since greater antiproteinuric effect of cilnidipine was reported by Fujita et.al. in CARTER study when compared with amlodipine [36], people try to elucidate possible mechanism which underlie how N-type calcium channel blockade contribute to renal protection. Late results from same group showed that cilnidipine elicited significantly higher antioxidant activity than amlodipine and this superior antioxidant activity of cilnidipine has been proposed, at least in part, for explaining greater antiproteinuric effect [91]. In previous study, we analyzed renal TBARS content and DHE staining as oxidative stress markers in cilnidipine treated SHR/ND rats. Cilnidipine, but not amlodipine, significantly inhibited the increase in TBARS content and DHE staining. In addition, administration of cilnidipine suppressed the increase in mRNA levels of both gp91phox and p22phox, whereas amlodipine had no effect on expression levels. Protein complex formation of p47phox or Rac-1 with p22phox of NADPH oxidase subunits, which are necessary for NADPH oxidase to produce superoxide [92], were significantly increased in SHR/ND. Cilnidipine significantly suppressed the increases in complex formation of p47phox or Rac-1 with p22phox of NADPH oxidase. In contrast, amlodipine did not affect these parameters at all. These founds suggested again, N-type calcium channel played a critical role in renal ROS production which is dependent on NADPH oxidase. The precise mechanism about how does N-type calcium channel contribute to renal ROS production is still controversial.

Catecholamines, such as norepinephrine, can induce oxidative damage in myocardium through reactive intermediates resulting from their auto-oxidation [93]. Renal sympathetic activation been proposed to induce oxidative stress and lead to oxidative injury in end-organs such as the kidney [94–96]. Recently we also proved that renal denervation significantly suppressed aortic regurgitation induced glomerular reactive oxidative stress (ROS) [97]. Therefore, N-type calcium channel may activate oxidative stress by inducing norepinephrine releases from renal sympathetic nerve terminal.
A growing body of evidence from clinical and experimental studies has indicated role of RAS in induction of oxidative stress in the kidney [98, 99]. Results from 66 type 2 diabetic patients of nephropathy showed treatment with an ARB for 8 weeks reduced the levels of urinary 8-epi-prostaglandin F2-α and 8-hydroxydeoxyguanosine, biochemical markers of oxidative stress [98]. Treatment of Wistar-Kyoto rats (WKY) with subcutaneous Ang II infusions from osmotic minipumps induced oxidative stress in association with increased expression of the p22phox component of NADPH oxidase and decreased expression of extracellular superoxide dismutase in the renal cortex [99]. Upregulation of protein and mRNA expressions of renal p47phox and iNOS were significantly attenuated by treatment with an ARB for 8 weeks reduced the levels of urinary 8-epi-prostaglandin F2-α and 8-hydroxydeoxyguanosine, biochemical markers of oxidative stress [98]. Treatment of Wistar-Kyoto rats (WKY) with subcutaneous Ang II infusions from osmotic minipumps induced oxidative stress in association with increased expression of the p22phox component of NADPH oxidase and decreased expression of extracellular superoxide dismutase in the renal cortex [99]. Upregulation of protein and mRNA expressions of renal p47phox and iNOS were significantly attenuated by candesartan in type 2 diabetic mice [100]. Thus N-type calcium blockade induced inhibition on renal oxidative stress may also be explained by reduction of local Ang II production.

Interestingly, our recent in vitro study showed exogenous Ang II increases DHE staining in cultured mice podocytes. This increase can be significantly attenuated by knock down N-type calcium channel [2], suggesting that besides paracrine action, N-type calcium channel also directly involved in intracellular signal transduction pathway in Ang II induced oxidative stress. Indeed, it has been proved that calcium influx can trigger activation of calcium-dependent protein phosphatase calcineurin and its substrate nuclear factor of activated T cells (NFAT) in podocytes [101]. Off note, EI Bekay et al. demonstrated Ang II induced intracellular signal for ROS synthesis is transduced, at least partially, through calcium-dependent signaling pathway [102]. Although some studies associated calcium influx in podocytes to transient receptor potential (TRP) channels, especially TRPC6, we could not exclude the possibility that other sources, such as VDCCs, also be responsible for increase of intracellular calcium. As indicated by Nijenhuis, knock down of TRPC6 resulted in significant reduction of 1-oleoyl-2-acetyl-sn-glycerolin (OAG)-stimulated calcium influx in cultured podocytes. However, calcium influx was not completely inhibited, suggested involvement of other channels [101]. Actually, a secondary activation of L-type calcium channel was reported to be caused by Ang II induced TRPC3/C6 activation in cardiac myocytes [103]. Although L-type calcium channel has been suggested was not involved in Ang II stimulated calcium influx in rat podocyte since long time ago [104]. To our knowledge, there were still no studies identified L-type calcium channels in podocyte. The inefficient effect of L-type calcium channel blocker on preventing calcium influx probably due to nearly undetectable expression of L-type calcium channel in podocyte. In contrast, highly expressed N-type calcium channel was identified by our group in both in vitro and in vivo experiments [2]. Taken together, N-type calcium channel activation can trigger renal oxidative stress by inducing norepinephrine release and local Ang II synthesis which ultimately contribute to renal damage. In addition, N-type calcium channel may also directly involve in intracellular signal transduction pathway of Ang II induced oxidative stress (Fig. 3).

**Fig. 3** Relation between N-type calcium channel and oxidative stress. N-type calcium channel mediated production of NE and Ang II will cause oxidative stress on renal cells. In addition, N-type calcium channel may also involve in intracellular oxidative signaling pathway by inducing calcium influx and subsequent activation of calcineurin (Fig. 3). NE: Norepinephrine; Ang II: angiotensin II; AT1: angiotensin II type 1 receptor; N-CC: N-type calcium channel; CaN: calcineurin; TRPC6: transient receptor potential channel 6.; OS: oxidative stress.

**Conclusion**

Since been reported predominantly distributed in neuronal cells, especially sympathetic neuronal cells, the physiological and pathological role of N-type calcium channel in kidney were always tend to be mainly explained by its neural control during past decades. Indeed, N-type calcium channel
was involved in modulating renal vascular tone and trigger some inflammatory and fibrotic signaling pathways through mediating neurotransmitter, such as norepinephrine, releases from renal nerve terminals. However, accumulating evidence from denervated animal models and in vitro studies emerges that N-type calcium channel was also expressed on renal cells, especially podocytes, other than neuronal cells and make distinct contribution to renal damage. N-type calcium channel mediated calcium influx could be the critical factor for these intracellular signaling transduction pathways. Further studies still are needed for clarifying precise mechanism for applying N-type calcium channel blockade as new clinical strategy for preventing renal damage.

Declarations

Conflict of interest The authors declared that they have no conflicts of interest to this work. We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ertel EA et al (2000) Nomenclature of voltage-gated calcium channels. Neuron 25(3):533–535
2. Fan YY et al (2010) Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. J Hypertens 28(5):1034–1043
3. Hirning LD et al (1988) Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. Science 239(4835):57–61
4. Claasbrummel B, Osswald H, Illes P (1989) Inhibition of N-type calcium channel in podocyte. J Hypertens 28(5):1034–1043
5. Pruneau D, Angus JA (1990) Omega-conotoxin GVIA is a potent inhibitor of sympathetic neurogenic responses in rat small mesenteric arteries. Br J Pharmacol 96(1):101–110
6. Rittenhouse AR, Zigmond RE (1991) Omega-conotoxin inhibits the acute activation of tyrosine hydroxylase and the stimulation of norepinephrine release by potassium depolarization of sympathetic nerve endings. J Neurochem 56(2):615–622
7. Fabi F et al (1993) Evidence for sympathetic neurotransmission through presynaptic N-type calcium channels in human saphenous vein. Br J Pharmacol 110(1):338–342
8. Wright CE et al (2000) Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. Br J Pharmacol 131(7):1325–1336
9. Motagally MA, Neshat S, Lomax AE (2009) Inhibition of sympathetic N-type voltage-gated Ca2+ current underlies the reduction in norepinephrine release during colitis. Am J Physiol Gastrointest Liver Physiol 296(5):G1077–G1084
10. Nedergaard OA (2000) Effect of omega-conotoxin GVIA on noradrenaline release from postganglionic sympathetic neu- rones in rabbit aorta. Pharmacol Toxicol 86(1):30–35
11. Konda T et al (2009) Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/fzrn. Am J Nephrol 30(2):155–161
12. Takahara A (2009) Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 27(2):124–139
13. Shiga T et al (2007) Influence of cilnidipine or nisoldipine on sympathetic activity in healthy male subjects. Heart Vessels 22(6):404–409
14. Ito K et al (2003) Clinical usefulness of a dual L/N-type Ca2+ channel blocker, cilnidipine, in patients with chronic heart failure: assessment with 123I-MIBG myocardial scintigraphy. Kaku Igaku 40(4):421–430
15. Sollner T et al (1993) SNAP receptors implicated in vesicle targeting and fusion. Nature 362(6418):318–324
16. Smith AB, Cunnane TC (1997) Multiple calcium channels control neurotransmitter release from rat postganglionic sympathetic nerve terminals. J Physiol 499(Pt 2):341–349
17. Ye S et al (2002) Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 15(8):717–724
18. Wu MS et al (2009) Protection of ischemic preconditioning on renal neural function in rats with acute renal failure. Chin J Physiol 52(Suppl):365–375
19. Kon V (1989) Neural control of renal circulation. Miner Electrolyte Metab 15(1–2):33–43
20. Schlaich MP et al (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361(9):932–934
21. Aritomi S et al (2010) The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet. Heart Vessels 25(6):549–555
22. Konno Y, Kimura K (2008) Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. Int Heart J 49(6):723–732
23. Yu AS et al (1992) Molecular characterization and nephron distribution of a family of transcripts encoding the pore-forming subunit of Ca2+ channels in the kidney. Proc Natl Acad Sci USA 89(21):10494–10498
24. Perez-Reyes E et al (1998) Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature 391(6670):896–900
25. Gordienko DV, Clausen C, Goligorsky MS (1994) Ionic currents and endothelin signaling in smooth muscle cells from rat renal resistance arteries. Am J Physiol 266(2 Pt 2):F325–F341
26. Inscho EW et al (1997) Agonist-induced calcium regulation in freshly isolated renal microvascular smooth muscle cells. J Am Soc Nephrol 8(4):569–579
27. Hansen PB et al (2000) Vascular smooth muscle cells express the alpha(1A) subunit of a P/Q-type voltage-dependent Ca(2+) channel, and it is functionally important in renal afferent arterioles. Circ Res 87(10):896–902
28. Nikitina E et al (2007) Voltage-dependent calcium channels of dog basilar artery. J Physiol 580(Pt. 2):523–541
29. Converse RL Jr et al (1992) Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327(27):1912–1918
30. Augustyniak RA et al (2002) Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 20(1):3–9
31. Neumann J et al (2004) Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 65(5):1568–1576
32. Salman IM et al (2011) Renal sympathetic nervous system hyperactivity in early streptozotocin-induced diabetic kidney disease. Neurourol Urodyn 30(3):438–446
33. Masuo K et al (2010) Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev 6(2):58–67
34. Kojima S, Shida M, Yokoyama H (2004) Comparison between cilnidipine and amlopidine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 27(6):379–385
35. Miwa Y et al (2010) Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection. Clin Exp Hypertens 32(6):400–405
36. Fujita T et al (2007) Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 72(12):1543–1549
37. Navar LG (1997) The kidney in blood pressure regulation and development of hypertension. Med Clin North Am 81(5):1165–1198
38. Navar LG et al (1999) Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 10(Suppl 12):S266–S272
39. Navar LG et al (1999) Concentrations and actions of intraluminal angiotensin II. J Am Soc Nephrol 10(Suppl 11):S189–S195
40. Kobori H et al (2007) The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59(3):251–287
41. Konda T et al (2005) The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 101(1):1–13
42. Konda T et al (2006) Effects of L/N-type calcium channel antagonists, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 29(5):933–937
43. Toba H et al (2011) L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats. Hypertens Res 34(4):521–529
44. Clayton SC, Haack KK, Zucker IH (2011) Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol 300(1):F31–F39
45. Wang TT et al (1998) Molecular mechanism(s) of action of norepinephrine on the expression of the angiotensinogen gene in opossum kidney cells. Kidney Int 54(3):785–795
46. Singh R et al (2003) Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 14(4):873–880
47. Vidotti DB et al (2004) High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 286(6):F1039–F1045
48. Zhang SL et al (2002) Essential role(s) of the intrarenal renin-angiotensin system in transforming growth factor-beta 1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in high glucose. J Am Soc Nephrol 13(2):302–312
49. Wolf G, Neilson EG (1993) Angiotensin II as a hypertrophicogenic cytokine for proximal tubular cells. Kidney Int Suppl 39:S100–S107
50. Tang SS et al (1995) Temperature-sensitive SV40 immortalized rat proximal tubule cell line has functional renin-angiotensin system. Am J Physiol 268(3 Pt 2:F435–F446
51. Loghman-Adham M et al (1997) A conditionally immortalized cell line from murine proximal tubule. Kidney Int 52(1):229–239
52. Durvasula RV et al (2004) Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 65(1):30–39
53. Yoo TH et al (2007) Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 71(10):1019–1027
54. Durvasula RV, Shankland SJ (2008) Activation of a local renin angiotensin system in podocytes by glucose. Am J Physiol Renal Physiol 294(4):F830–F839
55. Wu KL, Schmid-Schonbein GW (2011) Nuclear factor kappa B and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat. Hypertension 57(2):261–268
56. Giannoukakis N et al (2000) Protection of human islets from the effects of interleukin-1beta by adenosine receptor transfer of an I kappa B repressor. J Biol Chem 275(47):36509–36513
57. Mabley JG et al (2002) NFkappaB1 (p50)-deficient mice are not susceptible to multiple low-dose streptozotocin-induced diabetes. J Endocrinol 173(3):457–464
58. Arkan MC et al (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11(2):191–198
59. Sanchez-Nino MD et al (2010) TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm. https://doi.org/10.1155/2010/182958
60. Lee YJ, Han HJ (2008) Albumin-stimulated DNA synthesis is mediated by Ca2+/PKC as well as EGF receptor-dependent p44/42 MAPK and NF-kappaB signal pathways in renal proximal tubule cells. Am J Physiol Renal Physiol 294(3):F534–F541
61. Brasier AR et al (2000) Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 212(1–2):155–169
62. Jamaluddin M et al (2000) Angiotensin II induces nuclear factor (NF)-kappaB1 isoforms to bind the angiotensinogen gene acute-phase response element: a stimulus-specific pathway for NF-kappaB activation. Mol Endocrinol 14(1):99–113
63. Acers GW et al (2011) Contribution of a nuclear factor-kappaB binding site to human angiotensinogen promoter activity in renal proximal tubular cells. Hypertension 57(3):608–613
64. Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57(6):1446–1454
65. Ott M et al (2007) Mitochondria, oxidative stress and cell death. Apoptosis 12(5):913–922
66. Attia DM et al (2001) Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats. J Am Soc Nephrol 12(12):2585–2593
67. Meng S et al (2003) Oxidative stress in Dahl salt-sensitive hypertension. Hypertension 41(6):1346–1352
68. Chabarskivi T et al (2002) Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39(2):269–274
69. Jin L et al (2006) Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats. J Physiol Pharmacol 57(3):343–357
70. Sedek M et al (2010) Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 299(6):F1348–F1358
71. Brezniceanu ML et al (2008) Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes 57(2):451–459
72. Satoh M et al (2005) NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288(6):F1144–F1152
73. Gorin Y et al (2005) Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 280(47):39616–39626
74. Tojo A, Asaba K, Onozato ML (2007) Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin Ther Targets 11(8):1011–1018
75. Zager RA et al (1992) Increased proximal tubular cell catalytic iron content: a result, not a mediator of, hypoxia-reoxygenation injury. J Am Soc Nephrol 3(1):116–118
76. Haneda M et al (2003) Overview of glucose signaling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 14(5):1374–1382
77. Xia L et al (2007) Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells. Am J Physiol Endocrinol Metab 293(5):E1280–E1288
78. Xu Y et al (2011) Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells. Toxicol Appl Pharmacol. https://doi.org/10.1016/j.taap.2011.09.028
79. Kashihara N et al (2010) Oxidative stress in diabetic nephropathy. Curr Med Chem 17(34):4256–4269
80. Ide Y et al (2010) Pigment epithelium-derived factor inhibits advanced glycation end product-elicted mesangial cell damage by blocking NF-kappaB activation. Microvasc Res 80(2):227–232
81. Iqbal J, Zaidi M (2005) Molecular regulation of mechanotransduction. Biochem Biophys Res Commun 328(3):751–755
82. MacKenna DA et al (1998) Extracellular signal-regulated kinase and c-Jun NH2-terminal kinase activation by mechanical stretch is integrin-dependent and matrix-specific in rat cardiac fibroblasts. J Clin Invest 101(2):301–310
83. Zhang Y et al (2010) Mechanical strain-induced RhoA activation requires NADPH oxidase-mediated ROS generation in caveolae. Antioxid Redox Signal 13(7):959–973
84. Kim NH et al (2006) Redox dependence of glomerular epithelial cell hypertrophy in response to glucose. Am J Physiol Renal Physiol 290(3):F741–F751
85. Susztak K et al (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55(1):225–233
86. Hishikawa K et al (2009) Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney Int 76(2):230–231
87. Groemping Y et al (2003) Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell 113(3):343–355
88. Nankivell BJ et al (1994) The role of tubular iron accumulation in injury. J Am Soc Nephrol 3(1):116–118
89. Hisherama T et al (2003) Entacapone protects from angiotensin II-induced inflammation and renal injury. J Hypertens 21(12):2353–2363
90. Miyagawa K et al (2007) Increased oxidative stress impairs endothelial modulation of contractions in arteries from spontaneously hypertensive rats. J Hypertens 25(2):415–421
91. El Bekay R et al (2003) Oxidative stress is a critical mediator of angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 46(3):533–539
92. Ogawa S et al (2006) Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 47(4):699–705
93. Welch WJ et al (2005) Angiotensin-induced defects in renal oxygenation: role of oxidative stress. Am J Physiol Heart Circ Physiol 288(1):H22–H28
94. Fan Q et al (2004) Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 19(12):3012–3020
95. Nijenhuis T et al (2011) Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol 179(4):1719–1732
96. Fan Q et al (2004) Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 19(12):3012–3020
97. El Bekay R et al (2003) Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Cardiovasc Res 52(3):687–693
98. Ide Y et al (2010) Pigment epithelium-derived factor inhibits advanced glycation end product-elicted mesangial cell damage by blocking NF-kappaB activation. Microvasc Res 80(2):227–232
99. Iqbal J, Zaidi M (2005) Molecular regulation of mechanotransduction. Biochem Biophys Res Commun 328(3):751–755
100. MacKenna DA et al (1998) Extracellular signal-regulated kinase and c-Jun NH2-terminal kinase activation by mechanical stretch is integrin-dependent and matrix-specific in rat cardiac fibroblasts. J Clin Invest 101(2):301–310
101. Zhang Y et al (2010) Mechanical strain-induced RhoA activation requires NADPH oxidase-mediated ROS generation in caveolae. Antioxid Redox Signal 13(7):959–973
102. Onohara N et al (2006) TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J 21(12):2353–2363
103. Tie J, Zaidi M (2005) Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood 102(2):662–671
104. Onohara N et al (2006) TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J 21(12):2353–2363
105. Henger A et al (2003) Pigment epithelium-derived factor inhibits advanced glycation end product-elicted mesangial cell damage by blocking NF-kappaB activation. Microvasc Res 80(2):227–232
106. Iqbal J, Zaidi M (2005) Molecular regulation of mechanotransduction. Biochem Biophys Res Commun 328(3):751–755
107. MacKenna DA et al (1998) Extracellular signal-regulated kinase and c-Jun NH2-terminal kinase activation by mechanical stretch is integrin-dependent and matrix-specific in rat cardiac fibroblasts. J Clin Invest 101(2):301–310
108. Yatabe J et al (2009) Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II. Am J Physiol Renal Physiol 296(5):F1052–F1060
109. Zhang Y et al (2010) Mechanical strain-induced RhoA activation requires NADPH oxidase-mediated ROS generation in caveolae. Antioxid Redox Signal 13(7):959–973
110. Kashihara N et al (2010) Oxidative stress in diabetic nephropathy. Curr Med Chem 17(34):4256–4269
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.